GB2503187A - Composition for use in the treatment of neurodevelopmental disorders - Google Patents

Composition for use in the treatment of neurodevelopmental disorders Download PDF

Info

Publication number
GB2503187A
GB2503187A GB1115977.9A GB201115977A GB2503187A GB 2503187 A GB2503187 A GB 2503187A GB 201115977 A GB201115977 A GB 201115977A GB 2503187 A GB2503187 A GB 2503187A
Authority
GB
United Kingdom
Prior art keywords
genotype
ins
antagonist
compound
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1115977.9A
Other languages
English (en)
Other versions
GB201115977D0 (en
Inventor
Ayana Alice Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sussex
Original Assignee
University of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sussex filed Critical University of Sussex
Priority to GB1115977.9A priority Critical patent/GB2503187A/en
Publication of GB201115977D0 publication Critical patent/GB201115977D0/en
Priority to PCT/GB2012/052278 priority patent/WO2013038200A2/fr
Publication of GB2503187A publication Critical patent/GB2503187A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1115977.9A 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders Withdrawn GB2503187A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1115977.9A GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders
PCT/GB2012/052278 WO2013038200A2 (fr) 2011-09-15 2012-09-14 Troubles neurodéveloppementaux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1115977.9A GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders

Publications (2)

Publication Number Publication Date
GB201115977D0 GB201115977D0 (en) 2011-10-26
GB2503187A true GB2503187A (en) 2013-12-25

Family

ID=44908638

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1115977.9A Withdrawn GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders

Country Status (2)

Country Link
GB (1) GB2503187A (fr)
WO (1) WO2013038200A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte
WO2017083739A1 (fr) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Méthode de prédiction de la réponse d'un patient à un traitement par l'acide valproïque
EP3856156A2 (fr) * 2018-09-28 2021-08-04 Medizinische Hochschule Hannover (MHH) Traitement de tauopathies associées à une démence

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371793A2 (fr) * 1988-12-01 1990-06-06 Glaxo Group Limited Utilisation d'un dérivé de benzodioxinopyrroles pour la fabrication d'un médicament pour le traitement de l'ischémie cérébrale
EP0407016A2 (fr) * 1989-05-16 1991-01-09 Glaxo Group Limited Utilisation de dérivés du benzodioxinopyrrole pour l'obtention d'um médicament destiné au traitement de l'anxiété
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
EP0460912A2 (fr) * 1990-06-05 1991-12-11 Glaxo Group Limited Médicament pour le traitement des troubles sexuels

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760089A (en) 1972-04-27 1973-09-18 Westinghouse Electric Corp Electrical bushing assembly having resilient means enclosed within sealing means
ES8607311A1 (es) * 1984-04-24 1986-06-16 Glaxo Group Ltd Un procedimiento para la preparacion de compuestos aminoheterociclicos.
GB8526209D0 (en) 1985-10-23 1985-11-27 Glaxo Group Ltd Chemical process
GB9119466D0 (en) 1991-09-12 1991-10-23 Glaxo Group Ltd Chemical compounds
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB0002100D0 (en) * 2000-01-28 2000-03-22 Novartis Ag Organic compounds
CA2480695A1 (fr) * 2002-04-03 2003-10-09 Orion Corporation Composes polycycliques comme antagonistes puissants des recepteurs alpha2-adrenergiques
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
WO2007148185A2 (fr) 2006-06-21 2007-12-27 Pfizer Products Inc. 3-amino-pyrrolidino-4-lactames substitués
WO2008019431A1 (fr) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Procédé et compositions pour réguler simultanément la mémoire et l'humeur

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371793A2 (fr) * 1988-12-01 1990-06-06 Glaxo Group Limited Utilisation d'un dérivé de benzodioxinopyrroles pour la fabrication d'un médicament pour le traitement de l'ischémie cérébrale
EP0407016A2 (fr) * 1989-05-16 1991-01-09 Glaxo Group Limited Utilisation de dérivés du benzodioxinopyrrole pour l'obtention d'um médicament destiné au traitement de l'anxiété
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
EP0460912A2 (fr) * 1990-06-05 1991-12-11 Glaxo Group Limited Médicament pour le traitement des troubles sexuels

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dementia and Geriatric Cognitive Disorders, Vol. 25(4), 2008, (Mossello, Enrico et al), pages 372-379, ISSN: 1420-8008 *
Neuropharmacology, Vol. 60(2-3), 2011 (published February to March 2011), (Scullion, G. A.; Kendall, D. A.; Marsden, C. A.; Sunter, D.; Pardon, M.-C.), pages 223-234, ISSN: 0028-3908 *
Neuropsychopharmacology, Vol. 30(8), 2005, (Marrs, William et al), pages 1500-1510, ISSN: 0893-133X *
Neuroscience (Oxford, United Kingdom), Vol. 115(1), 2002, (Debeir, T. et al), pages 41-53, ISSN: 0306-4522 *

Also Published As

Publication number Publication date
WO2013038200A3 (fr) 2013-06-27
WO2013038200A2 (fr) 2013-03-21
GB201115977D0 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
EP2307000B1 (fr) Combinaison de pilocarpine et de méthimazol destinée au traitement de la maladie de charcot-marie-tooth et de troubles associés
US20110059998A1 (en) Kit, composition, product or medicament for treating cognitive impairment
CA3036984C (fr) Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3482754B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
US20230212221A1 (en) Novel Therapeutic Uses of Mu-Opiate Receptor Peptides
KR20220054724A (ko) 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
GB2503187A (en) Composition for use in the treatment of neurodevelopmental disorders
CA3083341C (fr) Traitement de cyclobenzaprine pour l'agitation, la psychose et le declin cognitif dans la demence et les etats neurodegeneratifs
KR100886578B1 (ko) 카바메이트 화합물을 포함하는 정신증 장애 예방용 또는 치료용 약제학적 조성물
CN112203675A (zh) 用于改善虚弱和衰老的方法
CA3179105A1 (fr) Association d'acetylleucine et de 4-aminopyridine ou d'acetazolamide pour traiter l'ataxie
KR20220079863A (ko) Kv7 채널 활성제의 사용 방법
Kohno et al. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum
AU2021389409A1 (en) Medicine for alleviating neuropathic pain
WO2020176807A1 (fr) Méthodes de traitement de la douleur du nerf trijumeau
CA2015336A1 (fr) Imidazodiazepines pour le traitement des symptomes neurologiques
EP4069232A1 (fr) Traitement de symptômes comportementaux et psychologiques chez des patients atteints de démence
COHEN et al. Patent 2727064 Summary
AU2014200818A1 (en) Kit, composition, product or medicament for treating cognitive impairment
WO2012139529A1 (fr) Inhibiteur de d-acide aminé oxydase pour la prévention et/ou l'inversion de la tolérance aux osopioïdes

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)